<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="../../external.html?link=http://www.w3.org/1999/xhtml"><head><title>Issues Berkeley Medical Journal</title>







  

  
  
  <meta http-equiv="content-language" content="English" />

  
  <meta name="description" content="ISSUES Berkeley Medical Journal--Berkeley undergraduate science, medicine, and health journalism." />

  
  <meta name="keywords" content="Issues, berkeley, university, california, journalism, science, medicine, undergraduate, journal, ISSUES Berkeley Medical Journal, Issues Berkeley" />

  
  <meta name="owner" content="ISSUES Berkeley Medical Journal" />

  
  <meta name="revisit-after" content="20 days" />

  
  <meta name="rating" content="General" />

  
  <meta name="robots" content="all" />

  
  <link rel="stylesheet" type="text/css" href="../style.css" /></head><body>
<div id="container">
<!--

******************************

	Header + Navigation

******************************

-->
<div id="header"><a href="../index.html"><img src="../images/logo.jpg" style="border: 0px solid ; float: left; width: 246px; height: 40px;" alt="" align="left" /></a></div>
<div id="nav">
<ul>
  <li><a href="contactus.html" title="Contact Us">Contact&nbsp;Us</a></li>
  <li><a href="archive.html" title="Publications">Archive</a></li>
  <li><a href="courseinfo.html" title="Course Info">Course Info</a></li>
  <li><a href="aboutus.html" title="About Us">About&nbsp;Us</a></li>
  <li><a href="index.html" title="Home">Home</a></li>
</ul>
</div>
<!--

******************************

	News Updates Column

******************************

-->
<div id="newsupdate">
<h1>Links and Updates</h1>
<div class="newstitle">.site<span>Navigation*</span></div>
<div id="MainText-left">
<ul>
  <li><a href="index.html" title="Home">Home</a></li>
  <li><a href="aboutus.html" title="About Us">About Us</a></li>
  <li><a href="courseinfo.html" title="Course Info">Course Info</a></li>
  <li><a href="archive.html" title="Publications">Archive</a></li>
  <li><a href="staff.html" title="Staff">Staff</a></li>
  <li><a href="joinus.html" title="Opportunities">Join Us<br />
    </a></li>
  <li><a href="advertise.html" title="Advertisements">Advertise</a></li>
  <li><a href="contactus.html" title="Contact Us">Contact Us</a></li>
</ul>
</div>
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<div class="newstitle"><span><br />
</span></div>
<br />
<p><b><br />
<br />
</b></p>
<div class="newstitle"><span><b><br />
</b></span></div>
<b><br />
</b>
<p><b><b><br />
<br />
<br />
<a href="../../external.html?link=http://www.ocf.berkeley.edu/">
<br />
</a> </b></b></p>
</div>
<!--

******************************

   Welcome Message IMG+TEXT

******************************

-->
<div class="rightcontainer">
<div id="welcome"><b><b>science. medicine. health.</b></b></div>
<div id="content">
<p style="text-align: center;"><a href="18.2_Xie_K_Imaging_Alzheimers_2.html"><small><span style="font-family: &quot;Trebuchet MS&quot;,Helvetica,sans-serif;">return to
previous page</span></small></a></p>
<p style="text-align: center;"><span style="font-family: &quot;Trebuchet MS&quot;,Helvetica,sans-serif;"><a href="18.2_Issue.html"><small>return
to issue</small></a><br />
</span></p>
<p><br />
</p>
<p style="font-style: italic;"><small>continued from Imaging Alzheimer's</small></p>
<p><small><br />
</small></p>
<p><small> &nbsp;&nbsp; Already, Bapineuzumab is an amyloid antibody
that is currently in Phase III of FDA testing.&nbsp; It has shown
promising results in trials, effectively reducing amyloid build-up in
mild to moderate AD.&nbsp; Some speculators say that PiB probably
played a large role in the drug&#8217;s success so far.&nbsp; PiB has made it
possible to not only see concrete results in drug trials, but to screen
for eligible trial patients. PiB thereby eliminates the guesswork
involved in figuring out if the drug did not work because it was flawed
or because the patient did not actually have AD. Bapineuzumab is one of
dozens of experimental AD drugs that are currently undergoing clinical
testing.&nbsp; With some luck, there will be some exciting results in
the near future.<br />
</small></p>
<p><small><br />
</small></p>
<p><small>&nbsp;&nbsp;&nbsp; More immediately relevant is that PiB can
detect abnormal amyloid levels in people who show no signs of cognitive
impairment.&nbsp; Studies done by Washington University have shown
about 20% of cognitively normal people have heightened amyloid levels,
and about half of those people go on to develop AD.&nbsp; This suggests
that while amyloid buildup can lead to a predisposition for AD it is
not the only factor.&nbsp; William Jagust, M.D of the Radiotracer
Development and Imaging Techniques department at UC Berkeley, says, &#8220;We
think what happens is that this amyloid sort of precipitates these
events that then just sort of takes off, at which point things really
start to deteriorate.&nbsp; It may well be that after the disease
starts to progress and pick up steam, getting rid of the amyloid might
not even make a difference at that point.&#8221; While it is clear that AD is
far more complex than just build-up of amyloid plaques, the presence of
amyloid is still an incredibly effective warning sign for the
disease.&nbsp; Furthermore, people testing positive for abnormal
amyloid can then be advised on preventative measures that can decrease
the chances that they will develop AD.<br />
</small></p>
<p><small><br />
</small></p>
<p><small>&nbsp;&nbsp;&nbsp; The development of the PiB tracer has
already made groundbreaking changes to the field of AD research and
will continue to do so.&nbsp; As Dr. Jagust says, &#8220;There&#8217;re still
things that we really don&#8217;t understand at all, but I think we&#8217;re
getting to a point where there&#8217;s a lot of opportunity to do things that
really could have an impact on people&#8217;s lives.&#8221; Hopefully, with PiB-PET
scans, researchers will be able to fully illuminate the cause of AD
and, more importantly, prevent it.<br />
</small></p>
<p><br />
</p>
<p style="text-align: center;"><a href="18.2_Xie_K_Imaging_Alzheimers_2.html"><small>return to previous
page</small></a></p>
<p style="text-align: center;"><a href="18.2_Issue.html"><small>return
to issue</small></a><br />
</p>
<p style="text-align: center;"><br />
</p>
<div style="text-align: right;"><span style="font-family: &quot;Trebuchet MS&quot;,Helvetica,sans-serif;" /></div>
</div>
</div>
<div id="footer"> Copyright © 2011 ISSUES Berkeley Medical Journal |
Designed by MockUp | <a href="mailto:bmjwebm@gmail.com">Contact
Webmaster </a><br />
Not an official University publication. Content not necessarily
reflective of UC Berkeley or the ASUC.</div>
</div>

</body></html>